Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2020-01-12 Board/Management Inform…
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Director Appointment / Resignation 1 page 61.0KB
Board/Management Information Classification · 100% confidence The document is an announcement from the Board of Lifespot Health Limited regarding the resignation of one director and the appointment of another. It focuses solely on changes in the company's board of directors. There is no financial data, report, or other regulatory filing content. This fits the definition of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or certification, so it is not RPA or RNS.
2020-01-12 English
PRODUCTION OF NEW SLIM LINE SMART VAPORISER FOR USA 2 pages 135.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated December 23, 2019, regarding the production commencement of a new slim line smart vaporiser product for the USA market. It includes product details, market strategy, and an update on lung injury related to vaping from the CDC. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The document is a corporate announcement about product development and market updates, typical of a Capital/Financing Update or general corporate announcement. Given the content focuses on production and market introduction of a new product and related health updates, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters and is a direct announcement, not a report publication notice or certification. Therefore, the classification is CAP with high confidence.
2019-12-22 English
Development Update Medical Cannabis Vaporiser and App 3 pages 241.1KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated December 6, 2019, providing a development update on a medical cannabis vaporiser and app. It discusses product features, market trends, and company information but does not contain financial statements, earnings data, or regulatory filings. The content is focused on product development and market updates rather than financial results or governance. The document length is about 5060 characters, which is relatively short and reads like a corporate announcement rather than a detailed report. There is no indication that this is a full financial report, audit, or regulatory filing. Therefore, the document best fits the category of a Capital/Financing Update (CAP) as it relates to product development and market positioning, which can be considered part of company updates relevant to investors and capital markets.
2019-12-05 English
Change of Director's Interest Notice 3 pages 173.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares held before and after the change, the nature of the interest, and transaction details. This matches the description of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is concise and focused solely on director share transactions, with no financial statements or other report content. Therefore, it fits the 'Director's Dealing' category (DIRS).
2019-11-28 English
Change of Director's Interest Notice 3 pages 265.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the interest, and transaction details. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3719 characters, which is consistent with a detailed notice of director's interest changes rather than a brief announcement or a full financial report. Therefore, the correct classification is Director's Dealing (DIRS).
2019-11-03 English
Appendix 4C - quarterly 5 pages 374.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the current quarter and year to date, including operating, investing, and financing activities. It also includes a compliance statement and notes referencing accounting standards. The document length is 8587 characters, which is substantial and contains actual financial data, not just an announcement or certification. The content aligns with a quarterly financial report providing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2019-10-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.